ArticleInternational journal of molecular sciences2026
CWH43 Suppresses Ferroptosis-Associated Vulnerability Through Redox Adaptation in Colorectal Cancer.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ferroptosis is an iron-dependent form of regulated cell death that has emerged as a potential vulnerability in cancer cells under therapeutic stress. However, the mechanisms by which colorectal cancer cells modulate ferroptosis susceptibility remain incompletely understood. In this study, we investigated the role of CWH43, a glycosylphosphatidylinositol-anchor biogenesis-related protein whose role in chemotherapy response has been unclear, in regulating redox balance and ferroptosis-associated vulnerability in colorectal cancer. Integrative analyses of clinical datasets, transcriptomic profiling, and functional experiments were performed using gain- and loss-of-function approaches in CRC cell models. We found that elevated CWH43 expression was associated with adverse clinical outcomes and reduced responsiveness to chemotherapy. Functionally, CWH43 attenuated ferroptosis-associated vulnerability by reducing intracellular reactive oxygen species and lipid peroxidation. Mechanistically, CWH43 promoted redox-adaptive programs involving activation of NRF2-dependent antioxidant signaling, upregulation of the cystine transporter SLC7A11, increased intracellular glutathione availability, and suppression of lipid peroxidation. Genetic or pharmacological disruption of SLC7A11 restored ferroptosis susceptibility and sensitized CWH43-overexpressing colorectal cancer cells to therapeutic stress, whereas ferrostatin-1 partially restored cell viability following erastin-containing treatments. Collectively, these findings identify CWH43 as a regulator of redox adaptation that modulates ferroptosis-associated vulnerability in colorectal cancer, providing insights into stress-adaptive survival mechanisms and chemotherapy resistance in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.